Plasma p-tau217 detects AD with high accuracy

New data reported at AAIC 2020 suggest that the blood-based biomarker p-tau217 can potentially detect changes in the brain 20 years before dementia symptoms occur. If confirmed in further studies, the findings could lead to a simple early blood test for Alzheimer’s disease (AD), indicating abnormal tau metabolism in the brain.

Researchers from Lund University, Sweden, and other centers in Colombia, Sweden, and the USA, evaluated plasma p-tau217 and plasma p-tau181 (identified as a promising biomarker in previous studies) in three cohorts with a total of 1,438 participants (including cognitively unimpaired subjects, and clinically diagnosed patients with mild cognitive impairment, AD dementia, and other non-AD neurodegenerative diseases).